{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T10:24:15Z","timestamp":1698575055955},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":6551,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1995,4]]},"abstract":"<jats:p>The pharmacokinetics of butorphanol tartrate given in a nasal spray with and without the co\u2010administration of sumatriptan succinate were studied in 24 healthy men and women. In this crossover design study, all subjects received 2 treatments: a single 1\u2010mg dose of butorphanol nasal spray and a 1\u2010mg dose of butorphanol nasal spray plus a single 6\u2010mg subcutaneous (SC) dose of sumatriptan. There was a two\u2010week washout period between sessions. Serial blood samples were collected and plasma samples analyzed using validated radioimmunoassay and high\u2010performance liquid chromatography\/electrochemical procedures to determine the concentrations of unchanged butorphanol and sumatriptan, respectively. There were no statistically significant differences for butorphanol between the 2 treatments on any of the following pharmacokinetic parameters: C<jats:sub>max<\/jats:sub>, t<jats:sub>max<\/jats:sub>, AUC, t<jats:sub>1\/2<\/jats:sub>, CL\/f, and V<jats:sub>z<\/jats:sub>\/f. Similarly, the pharmacokinetic parameters obtained for sumatriptan (given with butorphanol nasal spray) were comparable with the literature values obtained for a single 6\u2010mg SC dose of sumatriptan. These data show a lack of pharmacokinetic interaction between butorphanol nasal spray and sumatriptan. Butorphanol nasal spray and sumatriptan were well tolerated. The adverse experience profiles of butorphanol nasal spray were comparable between the treatments, with and without sumatriptan. It can be concluded that regimens of butorphanol nasal spray and sumatriptan need not be changed for either pharmacokinetic or safety considerations when the two compounds are co\u2010administered in treating acute migraine attacks.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1995.tb04085.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T19:11:10Z","timestamp":1362769870000},"page":"432-437","source":"Crossref","is-referenced-by-count":11,"title":["Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate"],"prefix":"10.1002","volume":"35","author":[{"given":"Nuggehally R.","family":"Srinivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen Chyi","family":"Shyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Upmalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi H.","family":"Barbhaiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","article-title":"Review of pharmacokinetics of butorphanol","author":"Shyu WC","journal-title":"Pain Quarterly"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03006021"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03006816"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976203359"},{"key":"e_1_2_1_6_2","first-page":"427","article-title":"Butorphanol and morphine: A double\u2010blind multiple intramuscular dose comparative safety and efficacy study in patients with postoperative pain","volume":"21","author":"Lippmen N","year":"1977","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_7_2","first-page":"116","article-title":"Double\u2010blind comparison of butorphanol, a new parenteral analgesic, and meperidine in the treatment of postoperative pain","volume":"22","author":"Comunale FL","year":"1977","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_8_2","first-page":"266","article-title":"Analgesic evaluation of butorphanol in patients with postoperative wound pain","volume":"19","author":"Bauer RO","year":"1976","journal-title":"Proc West Pharmacol Soc"},{"key":"e_1_2_1_9_2","first-page":"48","article-title":"A double\u2010blind clinical evaluation of butorphanol and pentazocine in the alleviation of pain following gynecological therapy","volume":"23","author":"Cater R","year":"1978","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975185part1547"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006057600400408"},{"key":"e_1_2_1_12_2","first-page":"19","volume-title":"Pharmacological and Biochemical Properties of Drug Substances","author":"Caruso FS","year":"1979"},{"key":"e_1_2_1_13_2","first-page":"231","article-title":"The pharmacology of butorphanol, a 3,14\u2010dihydroxymorphinan narcotic antagonist analgesic","volume":"220","author":"Pircio AW","year":"1976","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_1_14_2","first-page":"618","article-title":"GR43175 selectively constricts the canine carotid arterial bed via stimulation of 5\u2010HT1\u2010like receptors","volume":"93","author":"Brittain RT","year":"1989","journal-title":"Br J Pharmacol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0333102489009S10187","article-title":"Oral GR43175, a 5HT1\u2010like agonist, for treatment of the acute migraine attack: An international study\u2014preliminary results","volume":"9","author":"Dahlos C","year":"1989","journal-title":"Cephalagia"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/0333102489009S10185","article-title":"Subcutaneous GR43175 in the treatment of acute migraine: An international study","volume":"9","author":"Ferrari M","year":"1989","journal-title":"Cephalagia"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460210077033"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90079-V"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243050-00010"},{"key":"e_1_2_1_20_2","first-page":"160","article-title":"Transnasal butorphanol in the treatment of migraine headache pain","volume":"3","author":"Diamond S","year":"1992","journal-title":"Headache Quarterly, Current Treatment and Research"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600690211"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600820116"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000116756"},{"key":"e_1_2_1_24_2","first-page":"230","article-title":"Disposition of parenteral butorphanol in man","volume":"8","author":"Gaver RC","year":"1980","journal-title":"Drug Metab Disposition"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510140503"},{"key":"e_1_2_1_26_2","first-page":"34","article-title":"The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis","volume":"54","author":"Shyu WC","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.106"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1995.tb04085.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1995.tb04085.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T01:09:00Z","timestamp":1698282540000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1995.tb04085.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,4]]}},"alternative-id":["10.1002\/j.1552-4604.1995.tb04085.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04085.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,4]]}}}